Published in Hepatology on December 01, 2004
Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol (2010) 2.81
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg (2007) 1.82
Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer (2012) 1.58
Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol (2006) 1.48
The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One (2015) 1.46
Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: a propensity score analysis. Medicine (Baltimore) (2014) 1.41
Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol (2009) 1.36
Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. Int J Clin Oncol (2017) 1.14
The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer (2013) 1.13
Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol (2008) 1.13
Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer (2015) 1.10
Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol (2014) 1.02
Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One (2014) 0.97
Hepatic resection is justified for elderly patients with hepatocellular carcinoma. World J Surg (2008) 0.95
Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One (2014) 0.94
Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application : Hepatocellular carcinoma. Hepatol Int (2008) 0.92
Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol (2017) 0.91
Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br J Cancer (2014) 0.90
Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma. Medicine (Baltimore) (2015) 0.88
International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer (2014) 0.87
Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol (2008) 0.87
Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. World J Gastroenterol (2013) 0.84
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. Liver Cancer (2016) 0.83
Evolving therapies in the treatment of hepatocellular carcinoma. Biologics (2008) 0.83
Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma. World J Gastroenterol (2011) 0.83
Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma. World J Gastroenterol (2014) 0.83
Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol (2015) 0.82
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist (2012) 0.82
Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study. Liver Int (2014) 0.82
Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma. Chin Med J (Engl) (2015) 0.82
Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol (2015) 0.81
An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol (2014) 0.81
Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. World J Hepatol (2015) 0.80
A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection: A STROBE-Compliant Article. Medicine (Baltimore) (2016) 0.79
Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol (2007) 0.78
Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival. World J Gastroenterol (2014) 0.78
Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J Gastroenterol (2006) 0.78
Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. Dis Markers (2015) 0.78
A simple and effective prognostic staging system based on clinicopathologic features of intrahepatic cholangiocarcinoma. Am J Cancer Res (2015) 0.77
Evaluation of UICC-TNM and JSBS staging systems for surgical patients with extrahepatic cholangiocarcinoma. Langenbecks Arch Surg (2010) 0.77
Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma. J Gastroenterol (2008) 0.77
Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. Oncol Lett (2010) 0.77
Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma. World J Gastroenterol (2013) 0.76
Staging for hepatocellular carcinoma: treatment strategy matters. Hepatology (2005) 0.76
Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score. J Gastroenterol (2005) 0.76
Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer (2016) 0.75
FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. J Cancer Res Clin Oncol (2015) 0.75
What is the best staging system for hepatocellular carcinoma? J Gastroenterol (2006) 0.75
The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma. Cancer Med (2017) 0.75
Interaction between periodontitis and liver diseases. Biomed Rep (2016) 0.75
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. J Immunol Res (2015) 0.75
Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol (2015) 0.75
Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 ras. Chin J Cancer Res (2013) 0.75
Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma. Oncol Lett (2010) 0.75
Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Mol Clin Oncol (2016) 0.75
Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma. Hepat Med (2011) 0.75
A sub-centimeter HCC with bright loop appearance diagnosed by contrast-enhanced ultrasonography. J Med Ultrason (2001) (2010) 0.75
Early liver cancer: concepts, diagnosis, and management. Int J Clin Oncol (2005) 0.75
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer (2017) 0.75
Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett (2017) 0.75
Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science (2004) 7.29
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab (2007) 4.16
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol (2003) 2.87
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology (2007) 2.42
A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Nat Neurosci (2009) 2.42
Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol (2009) 2.31
Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med (2007) 1.97
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology (2013) 1.81
Assembly and maintenance of nodes of ranvier rely on distinct sources of proteins and targeting mechanisms. Neuron (2012) 1.75
Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy. Neuron (2013) 1.70
p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology (2003) 1.55
TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene (2004) 1.52
Effects of the omega-6:omega-3 fatty acid ratio of fat emulsions on the fatty acid composition in cell membranes and the anti-inflammatory action. JPEN J Parenter Enteral Nutr (2010) 1.49
Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res (2007) 1.47
Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One (2011) 1.39
Amyloid precursor protein cleavage-dependent and -independent axonal degeneration programs share a common nicotinamide mononucleotide adenylyltransferase 1-sensitive pathway. J Neurosci (2010) 1.37
Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology (2005) 1.33
Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J Neurosci (2013) 1.32
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology (2011) 1.32
Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem (2004) 1.29
Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma -dependent pathway. J Biol Chem (2002) 1.29
Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology (2008) 1.28
Surgical usefulness of indocyanine green as an alternative to India ink for endoscopic marking. Surg Endosc (2008) 1.28
Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol (2005) 1.27
Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology (2009) 1.25
Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res (2005) 1.23
The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg (2006) 1.22
Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. AJR Am J Roentgenol (2004) 1.20
Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J Neurosci (2012) 1.18
Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR Am J Roentgenol (2004) 1.17
Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. Cancer Res (2009) 1.17
Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology (2007) 1.17
Image-based screening identifies novel roles for IkappaB kinase and glycogen synthase kinase 3 in axonal degeneration. J Biol Chem (2011) 1.16
SCG10 is a JNK target in the axonal degeneration pathway. Proc Natl Acad Sci U S A (2012) 1.16
Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol (2009) 1.15
Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol (2003) 1.15
Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. AJR Am J Roentgenol (2003) 1.13
Postoperative ghrelin levels and delayed recovery from body weight loss after distal or total gastrectomy. J Surg Res (2005) 1.12
Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation. AJR Am J Roentgenol (2008) 1.12
Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol (2006) 1.11
Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology (2008) 1.10
Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology (2007) 1.10
Patients with pancreatic intraductal papillary mucinous neoplasms are at high risk of colorectal cancer development. Surgery (2006) 1.09
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol (2010) 1.08
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology (2010) 1.08
Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One (2012) 1.08
Spontaneous regression of hepatocellular carcinoma: report of a case. Surg Today (2005) 1.06
Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol (2012) 1.06
A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration. J Neurosci (2012) 1.05
Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int (2014) 1.05
Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol (2003) 1.04
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis (2011) 1.03
The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol (2007) 1.03
Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography. Oncology (2008) 1.03
Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastography. Intervirology (2008) 1.03
Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol (2007) 1.03
Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials (2010) 1.02
Two cases of acute necrotizing pancreatitis complicating after transcatheter arterial embolization for hepatocellular carcinoma. J Gastroenterol (2005) 1.01
Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol (2007) 1.01
Radiofrequency ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: an initial experience. Liver Int (2010) 1.01
Long-term follow-up of glucose tolerance function after pancreaticoduodenectomy: comparison between pancreaticogastrostomy and pancreaticojejunostomy. Surgery (2004) 1.00
Percutaneous ultrasound-guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. J Gastroenterol (2003) 1.00
Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proc Natl Acad Sci U S A (2011) 0.99
A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci (2012) 0.98
Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol (2014) 0.98
Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol (2011) 0.98
Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol (2011) 0.97
Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol (2008) 0.97
Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer (2013) 0.97
Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97
Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg (2005) 0.96
A simple and safe anastomosis in pancreaticogastrostomy using mattress sutures. Am J Surg (2008) 0.96
Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res (2006) 0.96
Hepatocellular carcinoma mimicking cavernous hemangioma on angiography and contrast enhanced harmonic ultrasonography. A case report. Hepatol Res (2003) 0.96
Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology (2007) 0.95
Using vital signs to diagnose impaired consciousness: cross sectional observational study. BMJ (2002) 0.95
Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg (2008) 0.94
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol (2014) 0.93
Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. Liver (2002) 0.93
Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia (2013) 0.93
Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol (2013) 0.93
Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology (2006) 0.92
Immortalization and characterization of human dental pulp cells with odontoblastic differentiation. Arch Oral Biol (2007) 0.92
Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol (2007) 0.92